Acetylation of E2 by P300 Mediates Topoisomerase Entry at the Papillomavirus Replicon

dc.contributor.authorThomas, Yanique
dc.contributor.authorAndrophy, Elliot J.
dc.contributor.departmentMicrobiology and Immunology, School of Medicineen_US
dc.date.accessioned2019-12-27T16:55:31Z
dc.date.available2019-12-27T16:55:31Z
dc.date.issued2019-03-21
dc.description.abstractHuman papillomavirus (HPV) E2 proteins are integral for the transcription of viral genes and the replication and maintenance of viral genomes in host cells. E2 recruits the viral DNA helicase E1 to the origin. A lysine (K111), highly conserved among almost all papillomavirus (PV) E2 proteins, is a target for P300 (EP300) acetylation and is critical for viral DNA replication (E. J. Quinlan, S. P. Culleton, S. Y. Wu, C. M. Chiang, et al., J Virol 87:1497-1507, 2013, https://doi.org/10.1128/JVI.02771-12; Y. Thomas and E. J. Androphy, J Virol 92:e01912-17, 2018, https://doi.org/10.1128/JVI.01912-17). Since the viral genome exists as a covalently closed circle of double-stranded DNA, topoisomerase 1 (Topo1) is thought to be required for progression of the replication forks. Due to the specific effect of K111 mutations on DNA unwinding (Y. Thomas and E. J. Androphy, J Virol 92:e01912-17, 2018, https://doi.org/10.1128/JVI.01912-17), we demonstrate that the E2 protein targets Topo1 to the viral origin, and this depends on acetylation of K111. The effect was corroborated by functional replication assays, in which higher levels of P300, but not its homolog CBP, caused enhanced replication with wild-type E2 but not the acetylation-defective K111 arginine mutant. These data reveal a novel role for lysine acetylation during viral DNA replication by regulating topoisomerase recruitment to the replication origin.IMPORTANCE Human papillomaviruses affect an estimated 75% of the sexually active adult population in the United States, with 5.5 million new cases emerging every year. More than 200 HPV genotypes have been identified; a subset of them are linked to the development of cancers from these epithelial infections. Specific antiviral medical treatments for infected individuals are not available. This project examines the mechanisms that control viral genome replication and may allow the development of novel therapeutics.en_US
dc.identifier.citationThomas, Y., & Androphy, E. J. (2019). Acetylation of E2 by P300 Mediates Topoisomerase Entry at the Papillomavirus Replicon. Journal of virology, 93(7), e02224-18. doi:10.1128/JVI.02224-18en_US
dc.identifier.urihttps://hdl.handle.net/1805/21603
dc.language.isoen_USen_US
dc.publisherAmerican Society for Microbiologyen_US
dc.relation.isversionof10.1128/JVI.02224-18en_US
dc.relation.journalJournal of Virologyen_US
dc.rightsPublisher Policyen_US
dc.sourcePMCen_US
dc.subjectDNA replicationen_US
dc.subjectE2en_US
dc.subjectP300en_US
dc.subjectPapillomavirusen_US
dc.subjectTopoisomerase 1en_US
dc.titleAcetylation of E2 by P300 Mediates Topoisomerase Entry at the Papillomavirus Repliconen_US
dc.typeArticleen_US
ul.alternative.fulltexthttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6430547/en_US
Files
Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
JVI.02224-18.pdf
Size:
781.91 KB
Format:
Adobe Portable Document Format
Description:
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.99 KB
Format:
Item-specific license agreed upon to submission
Description: